Collaborative Partnerships ReCode Therapeutics has established key partnerships with organizations such as PCD Foundation and Intellia Therapeutics, indicating potential collaboration opportunities for sales development tailored to shared initiatives.
Expert Leadership With the appointment of Dean J. Mitchell as Chairman of the Board of Directors, ReCode Therapeutics showcases a strong leadership team that can be leveraged for building strategic business relationships and sales engagements.
Innovative Technology ReCode's cutting-edge SORT lipid nanoparticle platform presents a compelling value proposition for sales representatives to engage potential clients by highlighting advanced genetic medicines technology and precise organ targeting capabilities.
Industry Recognition Recent news articles highlight ReCode Therapeutics' focus on developing genetic medicines for cystic fibrosis, which can be utilized as a sales pitch to showcase expertise and solutions aligned with market needs.
Strategic Expansion ReCode's launch of ThinkPCD.com and development of genetic therapies for CF signify market expansion and an opportunity for sales development to promote novel treatment solutions and genetic testing services to a wider audience.
51
$10M$50M
189$10M$50M
166$10M$50M
334$50M$100M
332$10M$50M
504$100M$1B
222$10M$50M
150$10M$50M
436$50M$100M
241$10M$50MReCode Therapeutics uses 8 technology products and services including WooCommerce, Font Awesome, jQuery Migrate, and more. Explore ReCode Therapeutics's tech stack below.
| ReCode Therapeutics Email Formats | Percentage |
| FLast@recodetx.com | 89% |
| First.Last@recodetx.com | 7% |
| FMiddleLast@recodetx.com | 2% |
| Last.First@recodetx.com | 2% |
Biotechnology ResearchMenlo Park, California & Dallas, Texas, United States51-200 Employees
ReCode Therapeutics is a clinical-stage genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics. ReCode’s selective organ targeting (SORT) lipid nanoparticle (LNP) platform is a next-generation, genetic medicines technology that enables precise delivery to target organs and cells beyond the liver.
Company Overview
Media & News
Funding & FinancialsReCode Therapeutics has raised a total of $50M of funding over 6 rounds. Their latest funding round was raised on Sep 19, 2023 in the amount of $50M.
ReCode Therapeutics's revenue is in the range of $10M
Funding & FinancialsReCode Therapeutics has raised a total of $50M of funding over 6 rounds. Their latest funding round was raised on Sep 19, 2023 in the amount of $50M.
ReCode Therapeutics's revenue is in the range of $10M
1-888-653-2347 
support@leadiq.com